

**Pediatric CIRB Meeting Agenda**

**March 12, 2026**

---

**I. Initial Review**

**ANBL2421**, Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) with or without Iberdomide in Children with Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy (Version Date 02/04/26)

---

**II. Continuing Review**

**ACNS2321**, A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas (Version Date 05/22/25)

---

**III. Continuing Review**

**ALTE2131**, Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer (Version Date 04/03/25)

---

**IV. Continuing Review**

**AOST2032**, A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (Version Date 07/30/25)

---